New targeted drug trial for tough-to-treat lung cancer
NCT ID NCT05378763
Summary
This study aimed to see if a new drug called poziotinib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has worsened after prior treatments. It directly compared how long each treatment kept the cancer from growing. The trial is currently suspended and not enrolling new participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bond Clinic, P.A.
Winter Haven, Florida, 33880, United States
Conditions
Explore the condition pages connected to this study.